New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms - PubMed (original) (raw)
Comparative Study
New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms
K Hultén et al. Antimicrob Agents Chemother. 1996 Dec.
Abstract
The capacity for intracellular growth is an important survival strategy for a large group of common pathogens. Helicobacter pylori, the etiological agent for gastritis and duodenal ulcer, has been shown by both in vivo and in vitro studies to have the capacity to invade epithelial cells. In vitro models are used to study the effect of antibiotics on microoganisms. Most investigations are performed in broth culture or on agar plates, but kinetic models for bacteria in broth have been described. We present a new, kinetic model adapted for intracellular pathogens. A glass chamber, with a metal rack fitting Falcon cell culture inserts, was connected to a pump by rubber tubes. Different tube diameters and pump speeds were evaluated, and the assay was designed to mimic the half-lives of the antibiotics in vivo, i.e., 11.5 h for azithromycin, 5 h for clarithromycin, and 1 h for amoxicillin. Monolayers of HEp-2 cells were grown in the inserts for 2 days, after which H. pylori (clinical strain 88-23), was added to the system. Internalization was allowed for 12 h, and extracellular H. pylori cells were eradicated with gentamicin. The inserts were moved to the glass chamber, containing medium with 12.5 mg of either amoxicillin or azithromycin per liter or 2.4 mg of clarithromycin per liter. This represents 12.5, 50, and 80 times the extracellular minimum bactericidal concentration value, respectively. Samples were taken at 0, 2, 4, 6, 8, and 24 h. The HEp-2 cells were lysed, and intracellular bacteria were counted by plating. Inserts with infected cells grown in drug-free medium were included as controls for each time interval. A 3-log10 reduction of H. pylori was achieved in the experiments with azithromycin, and a 4-log10 reduction was achieved in the clarithromycin experiments, while no intracellular effect was seen when amoxicillin was used. The antibiotic concentrations at the sampling intervals were 12.5, 3.1, 0.8, 0.2, 0.05, and 0 mg/liter for amoxicillin; 12.5, 11.5, 10, 9, 8, and 3 mg/liter for azithromycin; and 2.4, 1.8, 1.4, 1, 0.8, and 0 mg/liter for clarithromycin. This new model for pharmacokinetic studies provides a useful tool, with applications for a broad range of microorganisms.
Similar articles
- In-vitro activity of azithromycin in against intracellular Helicobacter pylori.
Hulten K, Cars O, Hjelm E, Engstrand L. Hulten K, et al. J Antimicrob Chemother. 1996 Mar;37(3):483-9. doi: 10.1093/jac/37.3.483. J Antimicrob Chemother. 1996. PMID: 9182105 - Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
Berry V, Thorburn CE, Knott SJ, Woodnutt G. Berry V, et al. Antimicrob Agents Chemother. 1998 Dec;42(12):3193-9. doi: 10.1128/AAC.42.12.3193. Antimicrob Agents Chemother. 1998. PMID: 9835514 Free PMC article. - Helicobacter pylori and gastric or duodenal ulcer.
[No authors listed] [No authors listed] Prescrire Int. 2016 Jan;25(167):18-23. Prescrire Int. 2016. PMID: 26942258 Review. - Azithromycin based triple therapy versus standard clarithromycin based triple therapy in eradication of Helicobacter pylori infection in Iran: a randomized controlled clinical trial.
Sarkeshikian SS, Iranikhah A, Ghadir MR. Sarkeshikian SS, et al. Turk J Gastroenterol. 2013;24(1):10-4. doi: 10.4318/tjg.2013.0540. Turk J Gastroenterol. 2013. PMID: 23794338 Clinical Trial. - Pharmacokinetic considerations in the eradication of Helicobacter pylori.
Klotz U. Klotz U. Clin Pharmacokinet. 2000 Mar;38(3):243-70. doi: 10.2165/00003088-200038030-00004. Clin Pharmacokinet. 2000. PMID: 10749519 Review.
Cited by
- A Diffusion-Based and Dynamic 3D-Printed Device That Enables Parallel in Vitro Pharmacokinetic Profiling of Molecules.
Lockwood SY, Meisel JE, Monsma FJ Jr, Spence DM. Lockwood SY, et al. Anal Chem. 2016 Feb 2;88(3):1864-70. doi: 10.1021/acs.analchem.5b04270. Epub 2016 Jan 15. Anal Chem. 2016. PMID: 26727249 Free PMC article. - Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.
Mueller M, de la Peña A, Derendorf H. Mueller M, et al. Antimicrob Agents Chemother. 2004 Feb;48(2):369-77. doi: 10.1128/AAC.48.2.369-377.2004. Antimicrob Agents Chemother. 2004. PMID: 14742182 Free PMC article. Review. No abstract available. - Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance.
Martínez JL, Baquero F. Martínez JL, et al. Clin Microbiol Rev. 2002 Oct;15(4):647-79. doi: 10.1128/CMR.15.4.647-679.2002. Clin Microbiol Rev. 2002. PMID: 12364374 Free PMC article. Review. - In vitro pharmacodynamic studies of activities of ketolides HMR 3647 (Telithromycin) and HMR 3004 against extracellular or intracellular Helicobacter pylori.
Gustafsson I, Engstrand L, Cars O. Gustafsson I, et al. Antimicrob Agents Chemother. 2001 Jan;45(1):353-5. doi: 10.1128/AAC.45.1.353-355.2001. Antimicrob Agents Chemother. 2001. PMID: 11120997 Free PMC article. - In vitro pharmacodynamics of the new ketolides HMR 3004 and HMR 3647 (Telithromycin) against Chlamydia pneumoniae.
Gustafsson I, Hjelm E, Cars O. Gustafsson I, et al. Antimicrob Agents Chemother. 2000 Jul;44(7):1846-9. doi: 10.1128/AAC.44.7.1846-1849.2000. Antimicrob Agents Chemother. 2000. PMID: 10858341 Free PMC article.
References
- J Clin Pathol. 1994 Aug;47(8):699-704 - PubMed
- Antimicrob Agents Chemother. 1994 May;38(5):1059-64 - PubMed
- Am J Gastroenterol. 1995 Sep;90(9):1407-10 - PubMed
- Gut. 1995 Jul;37(1):39-43 - PubMed
- Antimicrob Agents Chemother. 1995 Aug;39(8):1859-61 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical